Jensen A K, Rechnitzer C, Macklon K T, Ifversen M R S, Birkebæk N, Clausen N, Sørensen K, Fedder J, Ernst E, Andersen C Yding
Laboratory of Reproductive Biology, Juliane Marie Centre, Section 5712, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
Department of Paediatrics and Adolescent Medicine, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hum Reprod. 2017 Jan;32(1):154-164. doi: 10.1093/humrep/dew273. Epub 2016 Nov 5.
Is there an association between the need for medical puberty induction and the diagnosis or treatment received in girls who have undergone cryopreservation of ovarian tissue for fertility preservation?
There was a clear association between the intensity of treatment received and requirement for medical puberty induction but no association with the diagnosis.
Although it cannot be predicted which girls will become infertile or develop premature ovarian insufficiency (POI) following intensive chemotherapy or irradiation, patients who are at high risk of POI should be offered ovarian tissue cryopreservation (OTC). This includes girls who are planned to receive either high doses of alkylating agents, conditioning regimen before stem cell transplantation (SCT), total body irradiation (TBI) or high radiation doses to the craniospinal, abdominal or pelvic area.
STUDY DESIGN, SIZE, DURATION: This is a retrospective cohort study. In total, 176 Danish girls under 18 years of age have had OTC performed over a period of 15 years. An overview of the girls' diagnoses and mean age at OTC as well as the number of deceased is presented. Of the 176 girls, 38 had died and 46 girls were still younger than 12 years so their pubertal development cannot be evaluated yet. For the 60 girls who had OTC performed after 12 years of age, the incidence of POI was evaluated and in the group of 32 girls who were younger than 12 years at OTC, the association between the diagnosis and received treatment and the requirement for medical puberty induction was examined.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The need for medical puberty induction was assessed in 32 girls who were prepubertal at the time of OTC.
Indications for OTC were allogeneic SCT for leukaemia, myelodysplastic syndrome or benign haematological disorders, autologous SCT for lymphoma or sarcoma, and irradiation to the pelvis or to the spinal axis. The mean age at OTC of the 176 girls were 11.3 years. The two most prevalent diagnoses of the 176 girls were malignant tumours and malignant haematological diseases. Among the 32 prepubertal girls, 12 received high dose chemotherapy and either TBI prior to SCT or irradiation to the pelvis, abdomen or the spinal axis, 13 received high dose alkylating agents but no irradiation prior to SCT, six received alkylating agents as part of conventional chemotherapy and one patient had a genetic metabolic disorder and did not receive gonadotoxic treatment. Among these 32 girls, 23 did not undergo puberty spontaneously and thus received medical puberty induction. Among the nine girls, who went through spontaneous puberty, four had received high dose alkylating agents and five had received conventional chemotherapy.
All information was retrieved retrospectively from patient records, and thus some information was not available.
OTC should be recommended to all young girls, who present a high risk of developing ovarian insufficiency and/or infertility following high dose chemotherapy and/or irradiation.
STUDY FUNDING/COMPETING INTERESTS: The Childhood Cancer Foundation (2012-2016) and the EU interregional project ReproHigh are thanked for having funded this study. They had no role in the study design, collection and analysis of the data or writing of the report. The authors have no conflict of interest to disclose.
对于因生育力保存而进行卵巢组织冷冻保存的女孩,医学诱导青春期的需求与所接受的诊断或治疗之间是否存在关联?
所接受治疗的强度与医学诱导青春期的需求之间存在明显关联,但与诊断无关。
尽管无法预测哪些女孩在接受强化化疗或放疗后会出现不孕或发生卵巢早衰(POI),但对于有POI高风险的患者,应提供卵巢组织冷冻保存(OTC)。这包括计划接受高剂量烷化剂、干细胞移植(SCT)前的预处理方案、全身照射(TBI)或对颅脊髓、腹部或盆腔区域进行高剂量辐射的女孩。
研究设计、规模、持续时间:这是一项回顾性队列研究。在15年期间,共有176名18岁以下的丹麦女孩接受了OTC。呈现了女孩们的诊断情况、OTC时的平均年龄以及死亡人数。在这176名女孩中,38人已经死亡,46名女孩仍未满12岁,因此她们的青春期发育情况尚无法评估。对于60名12岁后接受OTC的女孩,评估了POI的发生率;对于32名OTC时未满12岁的女孩,研究了诊断和所接受治疗与医学诱导青春期需求之间的关联。
参与者/材料、环境、方法:对32名OTC时处于青春期前的女孩评估了医学诱导青春期的需求。
OTC的适应证包括用于白血病、骨髓增生异常综合征或良性血液系统疾病的异基因SCT、用于淋巴瘤或肉瘤的自体SCT,以及对盆腔或脊柱轴的照射。176名女孩OTC时的平均年龄为11.3岁。这176名女孩中最常见的两种诊断是恶性肿瘤和恶性血液系统疾病。在32名青春期前女孩中,12人在SCT前接受了高剂量化疗和TBI或对盆腔、腹部或脊柱轴的照射,13人在SCT前接受了高剂量烷化剂但未接受照射,6人接受了烷化剂作为传统化疗的一部分,1名患者患有遗传性代谢疾病且未接受性腺毒性治疗。在这32名女孩中,23人未自然进入青春期,因此接受了医学诱导青春期。在9名自然进入青春期的女孩中,4人接受了高剂量烷化剂,5人接受了传统化疗。
局限性 谨慎的原因:所有信息均从患者记录中回顾性获取,因此有些信息无法获得。
对于所有在高剂量化疗和/或放疗后有发生卵巢功能不全和/或不孕高风险的年轻女孩,均应推荐进行OTC。
研究资金/利益冲突:感谢儿童癌症基金会(2012 - 2016年)和欧盟区域间项目ReproHigh资助本研究。他们在研究设计、数据收集和分析或报告撰写中没有任何作用。作者没有利益冲突需要披露。